UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wa...
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and...
Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million...
Call moved to 5:30 a.m. PT / 8:30 a.m. ET on November 8th, 2018 BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage...
Sale of AgeX subsidiary will help support development of BioTime’s core programs Balance owed for remaining portion of transaction...
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that...
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina and Decrease of Drusen Density...
BioTime Shareholders To Receive One Share of AgeX Common Stock for Every 10 Shares of BioTime Common Stock BioTime, Inc. (NYSE American:...
Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee BioTime, Inc. (NYSE American: BTX), a...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.